Dimension Therapeutics (DMTX) Given “Buy” Rating at Chardan Capital
“We believe 2017 has been an even better year fundamentally, on the expansion of breakthrough results, the first 3 GT approvals in the US, sector late-stage momentum, sound safety, and other considerations below. We now make uniQure (Buy) a Chardan Top Pick for 2018 and a Chardan Top Pick in Gene Therapy for 2018.”,” Chardan Capital’s analyst wrote.
Other research analysts have also recently issued research reports about the company. Canaccord Genuity cut Dimension Therapeutics from a buy rating to a hold rating and lowered their price objective for the company from $12.00 to $3.41 in a research note on Wednesday, August 30th. Wells Fargo & Co cut Dimension Therapeutics from an outperform rating to a market perform rating and decreased their price target for the stock from $9.00 to $6.00 in a research note on Tuesday, October 3rd. Citigroup upgraded Dimension Therapeutics from a sell rating to a neutral rating and boosted their price target for the stock from $5.50 to $6.00 in a research note on Tuesday, October 3rd. Finally, ValuEngine upgraded Dimension Therapeutics from a strong sell rating to a sell rating in a research note on Saturday, September 30th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company’s stock. Dimension Therapeutics presently has a consensus rating of Hold and a consensus target price of $5.08.
Shares of Dimension Therapeutics (DMTX) remained flat at $$5.95 during trading hours on Friday. The firm has a market cap of $149.06 and a price-to-earnings ratio of -2.67. Dimension Therapeutics has a 12-month low of $1.05 and a 12-month high of $6.10. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.01 and a quick ratio of 3.33.
Dimension Therapeutics (NASDAQ:DMTX) last announced its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.20). The company had revenue of $4.48 million for the quarter. Dimension Therapeutics had a negative net margin of 378.28% and a negative return on equity of 240.95%. research analysts anticipate that Dimension Therapeutics will post -1.99 EPS for the current year.
Hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. raised its stake in shares of Dimension Therapeutics by 206.7% in the second quarter. Goldman Sachs Group Inc. now owns 80,471 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 54,231 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in shares of Dimension Therapeutics in the third quarter worth $600,000. Kassirer Asset Management Corp bought a new stake in shares of Dimension Therapeutics in the third quarter worth $952,000. Finally, K2 Principal Fund L.P. bought a new stake in shares of Dimension Therapeutics in the third quarter worth $960,000. Hedge funds and other institutional investors own 70.33% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Dimension Therapeutics (DMTX) Given “Buy” Rating at Chardan Capital” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/dimension-therapeutics-dmtx-given-buy-rating-at-chardan-capital/1780186.html.
About Dimension Therapeutics
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Ratings for Dimension Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.